DOCSLIB.ORG

Predicting NSAID Related Ulcers - Assessment of Clinical and Pathological Risk Factors and Importance of Differences in NSAID

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Predicting NSAID Related Ulcers - Assessment of Clinical and Pathological Risk Factors and Importance of Differences in NSAID Gut 1994; 35: 891-895 891 Predicting NSAID related ulcers - assessment of clinical and pathological risk factors and importance of differences in NSAID A S Taha, S Dahill, R D Sturrock, F D Lee, R I Russell Abstract posed to improve the yield of endoscopy. Although ulcers are often associated with These included simple age restrictionsl 2 and non-steroidal anti-inflammatory drugs strategies to characterise patients at risk of (NSAIDs) little is known about the benign or malignant ulcer disease.3-5 More feasibility of predicting their development recently it has been suggested that the detec- in patients taking NSAIDs. In addition, tion ofHelicobacterpylori by serology be used to the ulcerogenic potentials of the newer diagnose peptic ulcers in dyspeptic patients NSAIDs, taken on long term basis, have without the need for endoscopy.67 Despite not been compared with those of more the increased frequency of ulcers in patients established preparations. The aim of this taking non-steroidal anti-inflammatory drugs study was to identify the clinical and patho- (NSAIDs), very little is known about the risk logical characteristics of patients at a factors for their development. Nor is it clear higher risk of NSAID induced ulcers, whether the above observations would apply to measure the ulcerogenic potential of a NSAID patients. This is because: (1) NSAID- variety of NSAIDs, and test the effect induced ulcers can be completely asympto- of these potentials on the predictability matic8 9; (2) the precise contribution of of ulceration. Altogether 190 long term H pylori to NSAID related peptic damage is NSAID users were studied. The presence not fully defined; (3) the specificity of some of abdominal complaints, previous history serological tests for H pylori may be low in of ulcers, arthritis related physical dis- chronic NSAID users10; (4) there is a growing ability, anaemia, gastritis, and Helico- belief that the various NSAIDs may differ in bacter pylon status were all assessed as their ulcerogenic potentials.I 1-13 possible risk factors. NSAIDs were classi- This study aimed, therefore, to assess a fied into established drugs (group I), and group of clinical and pathological characteris- newer agents (group II). Group I included tics that might identify patients at a higher risk naproxen, indomethacin, diclofenac, of having NSAID related ulcers and to test the ketoprofen, piroxicam, and flurbiprofen. possibility that such risk might vary according Group II included fenbufen, nabumetone, to the type ofNSAID used. ibuprofen, etodolac, azapropazone, and tiaprofenic acid. Of 63 ulcers identified in the study group, 51 (81%) were seen in Patients and methods group I NSAID patients (51 of 132, 39%) Patients aged 18 years or over were recruited compared with 12 ulcers in group II (12 of from the rheumatology clinic provided they had 58, 21%), p<0.02; estimated relative risk osteoarthritis or adult rheumatoid arthritis. (ERR): 2.41). In group I, 25 ulcers were NSAIDs had to have been taken in therapeutic found in 38 patients with abdominal pain doses for at least four weeks. Patients were (25 of38, 66%, p<0-01, ERR: 5.03); 18 in 25 excluded if they had had gastric surgery, malig- (72%) patients with a previous history of nancy, or if they had taken anti-ulcer drugs or ulcers (p<0001, ERR: 5.77), 26 in 44 (59%/o) antibiotics within a week of endoscopy. patients with debilitating arthritis Blood was taken to measure the haemoglo- (p<0-001, ERR 3-64), and 35 in 73 (48%) bin concentration, erythrocyte sedimentation patients with H pylori associated gastritis rate (ESR), and C reactive protein (CRP). (p<001, ERR: 2.48). The presence ofthese Physical disability related to arthritis was factors in group II patients did not in- measured using the Health Assessment fluence the risk of ulceration. Group I Questionnaire.'4 Patients who scored 2 1 or NSAIDs were more likely to be associated more were considered to have debilitating Departments of with chemical gastritis and to intensify arthritis (finding much difficulty in performing Gastroenterology, Pathology, and H pylon related damage. Although silent their daily activities and needing to use several Rheumatology, ulcers are not uncommon in patients aids and devices). Informed consent was Glasgow Royal taking NSAIDs, recognition of the risk obtained and endoscopy was performed using Infirmary, Glasgow A S Taha factors might help predict a significant midazolam for sedation. Gastric antral biopsy S Dahill number (up to 81%), especially in those specimens were taken to test for H pyloni by R D Sturrock receiving group I NSAIDs. both histology (two specimens) and culture F D Lee (Gut 1994; 35: 89 1-895) (one specimen), as previously described.'5 R I Russell Gastritis was classified according to the Sydney Correspondence to: Dr A S Taha, GI Centre, system,'6 which also encompasses chemical Southern General Hospital, Over the years, several attempts have been and lymphocytic gastritis.17-20 Glasgow G5 1 4TF. made to the presence of peptic ulcers The following characteristics were assessed Accepted for publication predict 28 October 1993 and various screening policies have been pro- as possible risk factors: (1) upper abdominal 892 Taha, Dahill, Sturrock, Lee, Russell TABLE I Characteristcs ofpatients taking established (group I) or newer (group II) pathologists were not aware ofpatients' clinical NSAIDs details, and the study was approved by the All NSAID local ethics committee. Group I Group II patients (n = 132) (n = 58) (n = 190) Men 32 23 55 Results Women 100 35 135 Age (y) (median (IQ range)) 56 (46-60) 54 (46-66) 55 (46-62) A total of 190 patients was studied. Their Smokers 54 21 75 demographic characteristics are shown in Drinkers 61 24 85 Rheumatoid arthritis 107 39 146 Table I. Patients in both NSAID groups were Osteoarthritis 25 13 38 similar in terms of sex distribution, age, smok- Duration of NSAID (y) (median 2 (1-4) 1 (1-3) 2 (1-4) (IQ range)) ing and drinking habits, type of arthritis, and the duration of NSAID intake. In addition, there were no significant differences between TABLE II Duration ofarthritis, its activity, and details ofsecond line drugs the two groups with regard to the duration of arthritis, its activity (as judged by the erythro- All NSAID Group I Group II patients cyte sedimentation rate and C reactive (n= 132) (n= 58) (n= 190) protein), and the types of second line drugs as Duration of arthritis (y) (median 8 (4-14) 6 (2-18) 7 (3-14) shown in Table II. (IQ range)) The numbers of patients and ulcers in ESR (mm/h) (median (IQ range)) 24 (9-47) 22 (10-42) 23 (9-44) CRP (mg/i) (median (IQ range)) 13 (8-30) 11 (9-29) 12 (8-29) association with the various risk factors are Second line drugs: illustrated in Figures 1 and 2. Patients taking Gold 31 5 36 Sulphasalazine 31 15 46 group I NSAIDs had more ulcers than those Penicillamine 10 1 11 receiving group II drugs. The presence ofupper Hydroxychloroquine 13 4 17 abdominal complaints, a previous history of ulcers, debilitating arthritis, or H pylori signifi- ESR= sedimentation rate, CRP = C reactive protein. erythrocyte cantly increased the risk of having ulcers in group I NSAID patients. These factors did not symptoms, (2) previous history of ulcers, influence the risk of ulcers in group II patients, (3) debilitating arthritis, (4) anaemia (haemo- although more H pylon positive patients than globin less than 11 00 g/dl with iron deficiency Hpylori negative patients had ulcers. It is worth picture), (5) gastritis, and (6) H pylori status. noting that the ulcers described in this study NSAIDs were divided into two groups: group I were more common in the stomach (n=36) (older or established agents) including than in the duodenum (n=27). However, this naproxen, indomethacin, diclofenac, ketopro- pattern was reversed in smokers: 15 of23 ulcers fen, piroxicam, and flurbiprofen and group II (65%) in smokers were seen in the duodenum (newer agents) including fenbufen, nabume- compared with eight (35%) in the stomach tone, ibuprofen, etodolac, azapropazone, and (p<0 05), and this did not differ in the two tiaprofenic acid. The ulcerogenecity of most of NSAID groups. Also, group I patients included the newer preparations had been assessed 33 cases of anaemia (33 of 132, 25%) and 15 previously in short term trials only.12 13 ulcers (15 of 33, 45%) compared with seven of Statistical analyses included the x2 test, anaemia cases (seven of 58, 12%, p<0.05) and logistic regression, and the 95% confidence one ulcer (one of seven, 14%, p<0 05) in intervals for the estimated relative risk (odds group II patients. In addition, 18 ulcers were ratio) where appropriate. The endoscopist and found in 65 patients aged 60 years or over (28%), regardless of the type of NSAID, and men and women were equally effected. The estimated relative risk values and the All patients 950/o confidence intervals for the factors 140 included in Figure 1 are presented in Table III. ~~~~~~~~~~~Ulcers Patients with abdominal pain or a previous 100 .: Risk factor present history of ulcers had the highest values, while factor absent 80 ~ ~~~Risk those with anaemia had the lowest estimated 60. relative risk. Using logistic regression, it was found that only the type of NSAID (group I versus group II), the presence of abdominal pain, and a previous history of ulcers were 40 Al independent predictors of ulceration in the %0- 140 All patients Abdominal pain Past history of ulcers 140 study group as a whole. 120 z 100 TABLE iII The estimated relative risk (odds ratio (OR)) and 95% confidence intervals (95% CI) for the individual 80 riskfactorsfor ulcer development in patients taking group I 60 NSAIDs Riskfactors (OR) (95% CI) Previous history of ulcers 5-77 (2-2,15) 20 Abdominal pain 5 03 (2-27,11-2) Debilitating arthritis H pylori Anaemia Debilitating arthritis 3-64 (1-7, 7-9) Helicobacterpylori 2-48 (1-2,5- 12) Figure 1: The numbers ofulcers in the presence or absence ofthe various risk factors in Group I NSAID as a whole 2-41 (1-17,4-98) group I NSAID patients.
Load more

Recommended publications
  • Studies in Laboratory Animals to Assess the Safety of Anti-Inflammatory Agents in Acute Porphyria
    Ann Rheum Dis: first published as 10.1136/ard.46.7.540 on 1 July 1987. Downloaded from Annals of the Rheumatic Diseases, 1987; 46, 540-542 Studies in laboratory animals to assess the safety of anti-inflammatory agents in acute porphyria KENNETH E L McCOLL, GEORGE G THOMPSON, AND MICHAEL R MOORE From the University Department of Medicine, Western Infirmary, Glasgow SUMMARY The safety of various anti-inflammatory drugs in acute porphyria was assessed by examining their effect on rat hepatic haem synthesis. Azapropazone, chloroquine, and gold increased 6-aminolaevulinic acid (ALA) synthase activity, indicating that they are liable to precipitate porphyric crises. Aspirin, ibuprofen, indomethacin, ketoprofen, flurbiprofen, phenylbutazone, naproxen, prednisolone, and penicillamine did not increase ALA synthase activity and should be safe in porphyria. Though these animal studies can be used as a guide to prescribing in patients with acute porphyria, some caution is still required as species may vary in their response to inducing agents. Key words: chloroquine, azapropazone, gold, b-aminolaevulinic acid synthase. copyright. The acute hepatic porphyrias which comprise acute controlling enzyme of haem biosynthesis 6- intermittent porphyria, hereditary coproporphyria, aminolaevulinic acid (ALA) synthase in rat hepatic and variegate porphyria are examples of pharma- tissue. To confirm the reliability of the animal cogenetic disease. They are the result of deficien- model, phenobarbitone was also tested. For each cies of individual enzymes in the pathway of haem drug examined six male Sprague-Dawley rats re- biosynthesis and are inherited in an autosomal ceived the test drug and six control rats received the dominant fashion.2 Subjects with the genetic trait appropriate placebo solution.
    [Show full text]
  • Drug-Induced Peptic Ulcer Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by OAR@UM risk populations only.7 The prevalence of endoscopically confirmed gastrointestinal ulcers in NSAID users is quoted to be between 15% and 30%. Between 12% to 30% of NSAID-induced ulcers are gastric ulcers, whereas 2% to 19% are duodenal ulcers. NSAID-induced ulcers are symptomatic only in 1% of patients after three to six months and in 2 to 4% of patients after one year. Inappropriately they do not correlate well with pain because the analgesic action of NSAIDs may mask the ulcer pain.2 Drug-induced peptic Understanding the method by which NSAIDs cause gastric damage has helped in the development of prophylactic agents that ulcer disease 1 red uce their toxicity. The mechanism by which NSAIDs are thought to damage the Valerie Vella B Pharm(Hons), PgDip Clin Pharm (Aberdeen) gastrointestinal tract is four-fold. Clinical Pharmacist, St Luke’s Hospital, Guardamangia, Malta a) Topical injury Email: [email protected] Originally it was thought that NSAIDs damaged the gastric epithelium by Key words: Peptic ulcer, medicines, prostaglandins, gastrointestinal protection, intracellular accumulation of these drugs in gastrointestinal toxicity an ionised state.1 However the fact that enteric-coated formulations, pro-drugs, For more than a century, peptic ulcer disease has been a rectal and parenteral administration of 1 major cause of morbidity and mortality. Peptic ulcer disease NSAIDs still resulted in gastrointestinal is a heterogeneous group of disorders involving the damage despite the apparent absence of gastrointestinal tract and results from an imbalance between direct mucosal contact implies a minor role the aggressive forces of gastric acid and pepsin and the for topical injury1,2.
    [Show full text]
  • Contrasting Effects of Diclofenac and Ibuprofen on Active Imatinib Uptake Into Leukaemic Cells British Journal of Cancer, 2012; 106(11):1772-1778
    PUBLISHED VERSION Wang, Jueqiong; Hughes, Timothy Peter; Kok, Chung Hoow; Saunders, Verity Ann; Frede, Amity; Groot- Obbink, Kelvin Stuart; Osborn, M.; Somogyi, Andrew Alexander; D'Andrea, Richard James; White, Deborah Lee Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells British Journal of Cancer, 2012; 106(11):1772-1778 © 2012 Cancer Research UK From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ The electronic version of this article is the complete one and can be found online at: http://www.nature.com/bjc/journal/v106/n11/full/bjc2012173a.html PERMISSIONS http://www.nature.com/bjc/authors/submit.html#open BJC publishes BJC OPEN articles under a Creative Commons Attribution-Non commercial-Share Alike 3.0 Unported licence. This licence allows users to: share - to copy, distribute and transmit the work remix - to adapt the work Under the following conditions: attribution - users must attribute the work in the manner specified by the author or licensor (but not in any way that suggests an endorsement ) non commercial - users may not use this work for commercial purposes share alike - If users alter, transform, or build upon this work, they may distribute the resulting work only under the same or similar license to this one 20th May 2013 http://hdl.handle.net/2440/72375 British Journal of Cancer
    [Show full text]
  • Fenbufen | Medchemexpress
    Inhibitors Product Data Sheet Fenbufen • Agonists Cat. No.: HY-B1138 CAS No.: 36330-85-5 Molecular Formula: C₁₆H₁₄O₃ • Molecular Weight: 254.28 Screening Libraries Target: COX; Caspase Pathway: Immunology/Inflammation; Apoptosis Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 50 mg/mL (196.63 mM; Need ultrasonic) H2O : 0.67 mg/mL (2.63 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 3.9327 mL 19.6634 mL 39.3267 mL Stock Solutions 5 mM 0.7865 mL 3.9327 mL 7.8653 mL 10 mM 0.3933 mL 1.9663 mL 3.9327 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (9.83 mM); Suspended solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.83 mM); Clear solution BIOLOGICAL ACTIVITY Description Fenbufen (CL-82204) is an orally active non-steroidal anti-inflammatory drug (NSAID), with analgetic and antipyretic effects. Fenbufen has potent activity in a variety of animal model, including carageenin edema, UV erythema and adjuvant arthritis. Fenbufen has inhibitory activities against COX-1 and COX-2 with IC50s of 3.9 μM and 8.1 μM, respectively. Fenbufen is a caspases (caspase-1, 3, 4, 5, 9) inhibitor[1][2][3][4][5].
    [Show full text]
  • Individual Nsaids and Upper Gastrointestinal Complications a Systematic Review and Meta-Analysis of Observational Studies (The SOS Project)
    Drug Saf 2012; 35 (12): 1127-1146 SYSTEMATIC REVIEW 0114-5916/12/0012-1127 Adis ª 2012 Castellsague et al., publisher and licensee Springer International Publishing AG. This is an open access article published under the terms of the Creative Commons License ‘‘Attribution-NonCommercial-NoDerivative 3.0‘‘ (http://creativecommons.org/licenses/by-nc-nd/3.0/) which permits non-commercial use, distribution, and reproduction, provided the original work is properly cited and not altered. Individual NSAIDs and Upper Gastrointestinal Complications A Systematic Review and Meta-Analysis of Observational Studies (the SOS Project) Jordi Castellsague,1 Nuria Riera-Guardia,1 Brian Calingaert,2 Cristina Varas-Lorenzo,1 Annie Fourrier-Reglat,3 Federica Nicotra,4 Miriam Sturkenboom5 and Susana Perez-Gutthann1, on behalf of the investigators of the Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project 1 RTI Health Solutions, Barcelona, Spain 2 RTI Health Solutions, Research Triangle Park, NC, USA 3 Universite V. Segalen, Bordeaux, France 4 University Milan-Bicocca, Milan, Italy 5 Erasmus University Medical Center, Rotterdam, the Netherlands Abstract Background: The risk of upper gastrointestinal (GI) complications associated with the use of NSAIDs is a serious public health concern. The risk varies between individual NSAIDs; however, there is little information on the risk associated with some NSAIDs and on the impact of risk factors. These data are necessary to evaluate the benefit-risk of individual NSAIDs for clinical and health policy decision making. Within the European Community’s Seventh Framework Programme, the Safety Of non-Steroidal anti-inflammatory drugs (NSAIDs) [SOS] project aims to develop decision models for regulatory and clinical use of individual NSAIDs according to their GI and cardiovascular safety.
    [Show full text]
  • Long-Term Use of Anti-Inflammatory Drugs and Risk of Atrial Fibrillation
    ORIGINAL INVESTIGATION Long-term Use of Anti-inflammatory Drugs and Risk of Atrial Fibrillation Raffaele De Caterina, MD, PhD; Ana Ruigo´mez, MD, PhD; Luı´s Alberto Garcı´a Rodrı´guez, MD, MSc Background: Previous reports have described an asso- ratio [RR], 2.49; 95% confidence interval [CI], 1.56- ciation between the use of corticosteroids (steroidal anti- 3.97). However, we also found that the current use of inflammatory drugs [SAIDs]) and the risk of atrial fibril- NSAIDs was associated with an increased risk of chronic lation (AF). We sought to determine the existence of a AF (RR, 1.44; 95% CI, 1.08-1.91). Such risk was further similar association for non-SAIDs (NSAIDs). increased among long-term users with a treatment du- ration of longer than 1 year (RR, 1.80; 95% CI, 1.20- Methods: We identified patients aged 40 to 89 years with 2.72). The increased risk of chronic AF was not ex- a first-ever diagnosis of AF in 1996 in a United King- plained by the occurrence of heart failure. The use of dom primary care database and classified them as hav- NSAIDs was not associated with paroxysmal AF. ing paroxysmal or chronic AF. After validation with their primary care physicians, 1035 patients were confirmed Conclusions: The use of NSAIDs, as for SAIDs, is asso- as having incident chronic AF and 525 as having parox- ciated with an increased risk of chronic AF. Because the ysmal AF. Two separate nested case-control analyses es- use of anti-inflammatory drugs in general is a marker for timated the risk of first-time chronic and paroxysmal AF underlying inflammatory disorders, inflammation may among users of SAIDs and NSAIDs.
    [Show full text]
  • Non Steroidal Anti-Inflammatory Drugs
    Non Steroidal Anti‐inflammatory Drugs (NSAIDs) 4 signs of inflammation • Redness ‐ due to local vessel dilatation • Heat ‐ due to local vessel dilatation • Swelling – due to influx of plasma proteins and phagocytic cells into the tissue spaces • Pain – due to local release of enzymes and increased tissue pressure NSAIDs • Cause relief of pain ‐. analgesic • Suppress the signs and symptoms of inflammation. • Exert antipyretic action. • Useful in pain related to inflammation. Esp for superficial/integumental pain . Classification of NSAIDs • Salicylates: aspirin, Sodium salicylate & diflunisal. • Propionic acid derivatives: ibuprofen, ketoprofen, naproxen. • Aryl acetic acid derivatives: diclofenac, ketorolac • Indole derivatives: indomethacin, sulindac • Alkanones: Nabumetone. • Oxicams: piroxicam, tenoxicam Classification of NSAIDs ….. • Anthranilic acid derivatives (fenamates): mefenamic acid and flufenamic acid. • Pyrazolone derivatives: phenylbutazone, oxyphenbutazone, azapropazone (apazone) & dipyrone (novalgine). • Aniline derivatives (analgesic only): paracetamol. Clinical Classif. • Non selective Irreversible COX inhibitors • Non slective Reversible COX inhibitors • Preferential COX 2 inhibitors • 10‐20 fold cox 2 selective • meloxicam, etodolac, nabumetone • Selective COX 2 inhibitors • > 50 fold COX ‐2 selective • Celecoxib, Etoricoxib, Rofecoxib, Valdecoxib • COX 3 Inhibitor? PCM Cyclooxygenase‐1 (COX‐1): -constitutively expressed in wide variety of cells all over the body. -"housekeeping enzyme" -ex. gastric cytoprotection, hemostasis Cyclooxygenase‐2 (COX‐2): -inducible enzyme -dramatically up-regulated during inflammation (10-18X) -constitutive : maintains renal blood flow and renal electrolyte homeostasis Salicylates Acetyl salicylic acid (aspirin). Kinetics: • Well absorbed from the stomach, more from upper small intestine. • Distributed all over the body, 50‐80% bound to plasma protein (albumin). • Metabolized to acetic acid and salicylates (active metabolite). • Salicylate is conjugated with glucuronic acid and glycine. • Excreted by the kidney.
    [Show full text]
  • Inflammatory Drugs
    Solubility of Nonsteroidal Anti- diflunisal, etoricoxib, fenbufen, fentiazac, flufenamic inflammatory Drugs (NSAIDs) in acid, flurbiprofen, ibuprofen, indomethacin, ketopro- Neat Organic Solvents and Organic fen, ketorolac, lornoxicam, mefenamic acid, melox- Solvent Mixtures iam, nabumetone, naproxen, niflumic acid, nimesulide, phenylbutazone, piroxicam, rofecoxib, sodium diclof- William E. Acree enac, sodium ibuprofen, sodium naproxen, sodium J. Phys. Chem. Ref. Data 43, 023102 (2014) salicylate, tenoxicam, tolfenamic acid, and valdecoxib. IUPAC-NIST Solubility Data Series, Volume 102 http://dx.doi.org/10.1063/1.4869683 This IUPAC-NIST Solubility Data Series volume reviews experimentally determined solubility data for 33 non- To access recent volumes in the Solubility Data Series, visit http://jpcrd.aip.org/ and steroidal anti-inflammatory drugs (NSAIDs) dissolved search IUPAC-NIST Solubility Data Series in neat organic solvents and well-defined binary and ternary organic solvent mixtures retrieved from the published chemical and pharmaceutical litera- ture covering the period from 1980 to the beginning of 2014. Except for aspirin (2-acetoxybenzoic acid) and salicylic acid (2-hydroxybenzoic acid), very little Provisional Recommendations physical and chemical property data are available Provisional Recommendations are drafts of IUPAC in the published literature for NSAIDs prior to 1980. recommendations on terminology, nomenclature, and Solubility data are compiled and critically reviewed symbols made widely available to allow interested
    [Show full text]
  • Variable in Their Efficacy? a Description of Ion Trapping
    Annals of the Rheumatic Diseases 1993; 52: 241-243 241 HYPOTHESIS Why are non-steroidal anti-inflammatory drugs so variable in their efficacy? A description of ion trapping G A Ellis, D R Blake Hypothesis Non-steroidal anti-inflammatory drugs vary in Our hypothesis is that acidic non-steroidal their aqueous solubility, but most are highly anti-inflammatory drugs (NSAIDs) undergo albumin bound and will be co-distributed with ion trapping in acidotic tissue and that this this protein. Diffusion of an NSAID into the affects not only their gastrotoxicity, which is cell follows Fick's law, as it is dependent on the well known, but also their selectivity for, and concentration gradient across the plasma their efficacy in, inflammatory joint disease. membrane and the lipid/water partition Tissue acidosis may not be a feature of all coefficient of the drug molecule. chronic inflammatory disease states, but it does For weak acids, such as most NSAIDs, the occur in inflammatory joint disease and is effective concentration gradient is that of the highly variable depending on the extent of the non-ionised form, as ionised molecules are not mismatch between synovial perfusion and lipid soluble metabolic demand. This mismatch is influ- HD D- + H+ enced not only by disease activity, but also by Non-ionised Ionised joint movement, which causes transient hypoxic episodes. Interventions, such as rest The position ofthe equilibrium depends on the and drug treatment, would serve to reduce ion intrinsic ionisation constant of the molecule trapping and, therefore, NSAID efficacy (pKa) and on the pH value of the aqueous through their effects on disease activity.
    [Show full text]
  • The Acceleration of Articular Cartilage Degeneration in Osteoarthritis by Nonsteroidal Anti-Inflammatory Drugs Ross A
    WONDER WHY? THE ACCELERATION OF ARTICULAR CARTILAGE DEGENERATION IN OSTEOARTHRITIS WONDER WHY? The Acceleration of Articular Cartilage Degeneration in Osteoarthritis by Nonsteroidal Anti-inflammatory Drugs Ross A. Hauser, MD A B STRA C T introduction over the past forty years is one of the main causes of the rapid rise in the need for hip and knee Nonsteroidal anti-inflammatory drugs (NSAIDs) are replacements, both now and in the future. among the most commonly used drugs in the world for the treatment of osteoarthritis (OA) symptoms, and are While it is admirable for the various consensus and taken by 20-30% of elderly people in developed countries. rheumatology organizations to educate doctors and Because of the potential for significant side effects of the lay public about the necessity to limit NSAID use in these medications on the liver, stomach, gastrointestinal OA, the author recommends that the following warning tract and heart, including death, treatment guidelines label be on each NSAID bottle: advise against their long term use to treat OA. One of the best documented but lesser known long-term side effects The use of this nonsteroidal anti-inflammatory of NSAIDs is their negative impact on articular cartilage. medication has been shown in scientific studies to accelerate the articular cartilage breakdown In the normal joint, there is a balance between the in osteoarthritis. Use of this product poses a continuous process of cartilage matrix degradation and significant risk in accelerating osteoarthritis joint repair. In OA, there is a disruption of the homeostatic breakdown. Anyone using this product for the pain state and the catabolic (breakdown) processes of of osteoarthritis should be under a doctor’s care and chondrocytes.
    [Show full text]
  • Rheological and Mechanical Analyses of Felbinac Cataplasms by Using Box–Behnken Design
    pharmaceutics Article Rheological and Mechanical Analyses of Felbinac Cataplasms by Using Box–Behnken Design Jie Yang, Yishen Zhu * ID , Yongqin Diao and Caiyun Yin College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China; [email protected] (J.Y.); [email protected] (Y.D.); [email protected] (C.Y.) * Correspondence: [email protected]; Tel.: +86-189-0066-0563; Fax: +86-25-5813-9910 Received: 1 June 2018; Accepted: 5 July 2018; Published: 11 July 2018 Abstract: Felbinac, an active pharmaceutical ingredient (API) used clinically for the treatment of osteoarthritis, has poor solubility. Felbinac cataplasm product design was investigated using rheological and mechanical analyses. Experiments using a response surface methodology based on Box–Behnken design (BBD) incorporated three independent variables: the proportions of partially neutralized polyacrylate (NP800), dihydroxyaluminum aminoacetate (DAAA), and felbinac. Statistically significant quadratic models obtained using BBD demonstrated optimal NP-800, DAAA, and felbinac cataplasm proportions of 4.78–5.75%, 0.30–0.59%, and 0.70–0.90%, respectively. Felbinac cataplasms exhibited “gel-like” mechanical property with predominantly elastic behavior. Rheological studies correlated increasing NP-800 and DAAA concentrations with increased complex modulus (G*) values that were inversely related to peeling strength. Frequency sweep and creep tests revealed decreasing tan θ values with increasing NP-800 and DAAA concentrations. G’ and G” values were higher for higher NP-800 and DAAA levels, although G” values decreased with increasing DAAA concentration. Response surface methodology was applied to develop mathematical models. Variance analysis showed that the quadratic model effectively predicted felbinac and matrix material interactions, with two verification samples upholding model predictions.
    [Show full text]
  • COX-2 Chronology C J Hawkey
    1509 LEADING ARTICLE Gut: first published as 10.1136/gut.2005.065003 on 13 October 2005. Downloaded from COX-2 chronology C J Hawkey ............................................................................................................................... Gut 2005;54:1509–1514. doi: 10.1136/gut.2005.065003 The role of selective cyclooxygenase (COX)-2 inhibitors in N 1859 Hammond Kolbe synthesises salicylic acid, with industrial scale production in 1874.7 medical practice has become controversial since evidence Salicylic acid is bitter and irritates the mouth emerged that their use is associated with an increased risk and stomach. of myocardial infarction. Selective COX-2 inhibitors were N 1863 Friedrich Bayer and Friedrich Weskott found a dye manufacturing company employ- seen as successor to non-selective non-steroidal anti- ing six people in Wuppertal-Barmen.8 inflammatory drugs, in turn successors to aspirin. The N 1886 Bayer manufacture phenacetin from a importance of pain relief means that such drugs have waste product of a benzo dye. What starts as a always attracted attention. The fact that they work through supplement to dye manufacture is to become the company’s more profitable and dominant inhibition of cyclooxygenase, are widespread, and have activity18 multiple effects also means that adverse effects that were unanticipated (even though predictable) have always THE ASPIRIN YEARS emerged. In this paper I therefore present an historical N 1897 Motivated by his father’s intolerance of perspective so that the lessons of the past may be applied salicylic acid, Felix Hoffman synthesises acetyl salicylic acid, named aspirin (derived from to the present. Acetyl Spirea).12910 This had been done ........................................................................... before in 1853 (Carl Friedrich Gerhardt) and 1869 (Kraut) but Hoffman’s method is quan- titative (mixing salicylic acid and acetic hydride 2:3 before adding acetic acid) and yields pure stable aspirin.12 Aspirin causes 1066 AND ALL THAT less dyspepsia than salicylic acid.
    [Show full text]